Low-molecular-weight heparin in outpatient treatment of DVT

American Family Physician

Volumn 59, Issue 4, 1999, Pages 945-952

  Yeager, Bryan F ^a   Matheny, Samuel C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT EDUCATION; REVIEW; THROMBOCYTOPENIA;

ACUTE DISEASE; AMBULATORY CARE; ANTICOAGULANTS; CLINICAL PROTOCOLS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PARTIAL THROMBOPLASTIN TIME; PATIENT EDUCATION; PATIENT SELECTION; VENOUS THROMBOSIS;

EID: 0033557869     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Howard PA. Dalteparin: a low-molecular-weight heparin. Ann Pharmacother 1997;31:192-203.
2. Schafer AI. Low-molecular-weight heparin - an opportunity for home treatment of venous thrombosis [Editorial]. N Engl J Med 1996;334:724-5.
3. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
4. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
5. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
6. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-9.
7. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98 [Published erratum in N Engl J Med 1997;337:1567].
8. Heaton D, Pearce M. Low molecular weight versus unfractionated heparin. A clinical and economical appraisal. Pharmacoeconomics 1995;8:91-9.
9. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29:892-905
10. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 suppl 1): 258S-75S.
11. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994;309:299-304.
12. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-7.
13. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a metaanalysis. Am J Med 1996;100:269-77.
14. Valentine KA, Hull RD, Pineo GF. Low-molecular-weight heparin therapy and mortality. Semin Thromb Hemost 1997;23:173-8.
15. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7 [Published erratum in N Engl J Med 1997;337:1251].
16. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
17. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
18. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337:657-62.
19. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of patients with venous thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital [Abstract]. Proceedings of the 40th annual meeting of the GTH, Interlaken, Switzerland, February 1996. Ann Hematol 1996;72(suppl 1):A1-92.
20. Santoro A. Outpatient treatment of uncomplicated deep vein thrombosis: an overview of program development. J Man Care Pharm 1997;3:170-4.
21. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Health Syst Pharm 1997;54:1968-72.
22. Hull RD, Raskob GE, Rosenbloom D, Pineo GF, Lerner RG, Gafni A, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289-94.